Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of monoclonal antibodies for the treatment of various forms of cancer. It focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Its products include Pritumumab, CLNH5, and MultiPharm. The company was founded by Mark C. Glassy on March 3, 2014 and is headquartered in North Palm Beach, FL.